Reversal of severe graft-versus-host disease after nonmyeloablative matched unrelated donor stem cell transplant by infusion of backup autologous peripheral blood stem cells [4]

Bone Marrow Transplantation

Volumn 36, Issue 3, 2005, Pages 267-268

  Khan, S A ^a   Moreb, J S ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BUSULFAN; CYCLOPHOSPHAMIDE; DACLIZUMAB; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; INFLIXIMAB; LOMUSTINE; MELPHALAN; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PAMIDRONIC ACID; PREDNISONE; TACROLIMUS; THALIDOMIDE; THYMOCYTE ANTIBODY; VINCRISTINE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CASE REPORT; CHIMERA; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENERAL CONDITION DETERIORATION; HUMAN; HUMERUS FRACTURE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MULTIPLE MYELOMA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PATHOLOGIC FRACTURE; PLASMA CELL; PRIORITY JOURNAL; SALVAGE THERAPY; SYMPTOMATOLOGY; TOTAL PARENTERAL NUTRITION; TREATMENT OUTCOME;

BIOPSY; BONE MARROW; BONE MARROW CELLS; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; MULTIPLE MYELOMA; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; STEM CELLS; STEROIDS; TIME FACTORS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 23744509563     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705033     Document Type: Letter

References (10)

1. Schwartz JM, Wolford JL, Thornquist MD et al. Severe gastrointestinal bleeding after hematopoietic cell transplantation, 1987 1997: incidence, causes, and outcome. Am J Gastroenterol 2001; 96: 385-393.
2. Arai S, Margolis J, Zahurak M et al. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 2002; 8: 155-160.
3. Nademanee A, Schmidt GM, Parker P et al. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone. Blood 1995; 86: 1228-1234.
4. Van Lint MT, Uderzo C, Locasciulli A et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood 1998; 92: 2288-2293.
5. Ricordi C, Tzakis AG, Zeevi A et al. Reversal of graft-versus-host disease with infusion of autologous bone marrow. Cell Transplant 1994; 3: 187-192.
6. Passweg JR, Orchard K, Buergi A et al. Autologous/syngeneic stem cell transplantation to treat refractory GvHD. Bone Marrow Transplant 2004; 34: 995-998.
7. Pusic I, Pavletic SZ, Kessinger A et al. Pseudoautologous blood stem cell transplantation for refractory chronic graft-versus-host disease. Bone Marrow Transplant 2002; 29: 709-710.
8. Weiss L, Slavin S. Prevention and treatment of graft-versus-host disease by down-regulation of anti-host reactivity with veto cells of host origin. Bone Marrow Transplant 1999; 23: 1139-1143.
9. Kuwana M, Kaburaki J, Wright TM et al. Induction of antigen-specific human CD4(+) T cell anergy by peripheral blood DC2 precursors. Eur J Immunol 2001; 31: 2547-2557.
10. Hoffmann P, Ermann J, Edinger M et al. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002; 196: 389-399.